Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated

The Invesco QQQ Trust ETF&nbsp;($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was up 0.56% in Friday’s pre-market trading on h...

Why Is Invesco QQQ Trust ETF (QQQ) Rising Today, 5/22/2026?

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was up 0.66% in Wednesday’s pre-market trading, ahead...

Why Is Invesco QQQ Trust ETF (QQQ) Rising Today, 5/20/2026?

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insmed (INSM) and Personalis (PSNL) with bullish sen...

Analysts Are Bullish on These Healthcare Stocks: Insmed (INSM), Personalis (PSNL)

The Invesco QQQ Trust ETF&nbsp;($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was down 0.61% in Tuesday’s pre-market trading a...

Why Is Invesco QQQ Trust ETF (QQQ) Falling Today, 5/19/2026?

Schwab U.S. Dividend Equity ETF&nbsp;($SCHD) and NEOS Nasdaq-100 High Income ETF&nbsp;($QQQI) both appeal to income investors, but they generate di...

SCHD vs. QQQI: Which Dividend ETF Offers More Income Today?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insmed (INSM), Astrana Health (ASTH) and Baxter International (BA...

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Astrana Health (ASTH) and Baxter International (BAX)

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was down 0.29% on Monday morning, at the time of writ...

Invesco QQQ Trust ETF (QQQ) Daily Update, 5/18/2026

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Insmed today and set a price target of $214.00. Zemansky covers the He...

Bank of America Securities Sticks to Its Buy Rating for Insmed (INSM)

The Invesco QQQ Trust ETF&nbsp;($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was down 0.11% in Monday’s pre-market trading du...

Why Is Invesco QQQ Trust ETF (QQQ) Falling Today, 5/11/2026?

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Insmed on May 8 and set a price target of $200.00. The company’s shares closed la...

Stifel Nicolaus Remains a Buy on Insmed (INSM)

Jefferies analyst maintained a Buy rating on Insmed today and set a price target of $185.00. Insmed has an analyst consensus of Strong Buy, with a ...

Jefferies Remains a Buy on Insmed (INSM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NewAmsterdam Pharma Company (NAMS), Insmed (INSM) an...

Wall Street Analysts Are Bullish on Top Healthcare Picks

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was up 0.06% in Thursday’s pre-market trading on hope...

Why Is Invesco QQQ Trust ETF (QQQ) Inching Higher, 5/7/2026?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on HeartFlow, Inc. (HTFL), Hims & Hers Health (HIMS) and Insmed (INS...

Analysts Offer Insights on Healthcare Companies: HeartFlow, Inc. (HTFL), Hims & Hers Health (HIMS) and Insmed (INSM)

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was down 0.03% in Monday’s pre-market trading amid un...

Invesco QQQ Trust ETF (QQQ) Daily Update, 5/4/2026

The Invesco QQQ Trust ETF ($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was up 0.12% in Friday’s pre-market trading amid a de...

Why Is Invesco QQQ Trust ETF (QQQ) Rising Today, 5/1/2026?

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on United Therapeutics (UTHR), Insmed (INSM) and Mann...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: United Therapeutics (UTHR), Insmed (INSM) and MannKind (MNKD)

The Invesco QQQ Trust ETF&nbsp;($QQQ), which tracks the performance of the Nasdaq 100 Index (NDX), was down 0.04% in Monday’s pre-market trading as...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INSM	$106.24	-3.00%	2.43M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INSM	$106.24	-3.0%	2.43M
3
4
5
6

INSM

INSM

Dividend Overview

Get Insmed Incorporated Data in Excel

Get Insmed Incorporated Data in Excel